Peptide · Research Monograph · Synthetic GHRH(1-44) analog (trans-3-hexenoic acid-modified)

Tesamorelin

Growth Hormone Release Studies

Tesamorelin is a synthetic version of growth hormone releasing hormone, or GHRH. The sequence matches the full 44 amino acid human hormone. A chemical group added to one end protects it from an enzyme called DPP-4, which would otherwise break it down quickly. Research has measured growth hormone output and how fat tissue is distributed in study models.

Formula
C221H366N72O67S
Mol. weight
5135.89 Da
Length
44 residues
CAS
218949-48-5

For laboratory research use only - not for human or animal use

Tesamorelin vial from the Eon Peptides research catalog
Tesamorelin · 10mg · catalog photograph

The molecule, in three dimensions

C221H366N72O67S5135.89
Drag to turn
Residues · hover to locate44 residues
Heavy atoms
361
Bonds
363
Composition
C221 N72 O67 S1
Rings
3
Metal centre
None
Chain length
44 residues

Every heavy atom is placed from the sequence with ideal bond lengths and angles, so the connectivity is exact. The pose is idealised, an ideal helix, and is not a measured conformation. Identity for the lot in stock is confirmed by LC-MS on its certificate.

Molecular data

Molecular formulaC221H366N72O67S
Molecular weight5135.89 Da
SequenceModified GHRH(1-44) analog (trans-3-hexenoic acid-GRF(1-44)-amide)
Sequence length44 residues
CAS / identifier218949-48-5
Physical formLyophilized Powder
Available sizes10mg

How it works

  1. GHRH-R Agonism

    Growth Hormone Secretagogue

    Tesamorelin is a synthetic trans-3-hexenoic acid-modified analog of human GHRH(1-44). It binds and activates pituitary GHRH receptors, stimulating endogenous growth hormone (GH) secretion while preserving normal pulsatile GH release patterns - unlike exogenous GH administration.

    • Selective GHRH receptor agonism
    • Pulsatile GH secretion physiology retained in models
    • Downstream IGF-1 production measured
  2. Lipolysis

    Visceral Adipose Signalling

    Tesamorelin is studied for GH-mediated lipolytic signalling in visceral adipose tissue. GH is associated with hormone-sensitive lipase activity in adipocytes and free fatty acid release from visceral depots. An approved pharmaceutical formulation exists; this research material is not it.

    • GH-dependent hormone-sensitive lipase activity measured
    • Visceral (not subcutaneous) depot selectivity
    • Lean body mass measured in research models
  3. Neuroprotection

    Cognitive & Brain Research

    Research examines tesamorelin in relation to brain structure and function via IGF-1 signalling. Studies in older adults with mild cognitive impairment report changes in regional grey matter volume and functional connectivity. GH/IGF-1 axis modulation is one hypothesised mechanism.

    • Raised circulating IGF-1, which crosses the blood-brain barrier
    • Associated with changes in cortical gray matter volume
    • Under investigation for cognitive aging research models

What the research shows

  1. Metabolic

    Visceral Fat & Body Composition

    Visceral adipose signalling is the principal focus of tesamorelin research. The mechanism studied is GH-driven lipolysis in visceral depots, with limited effect on subcutaneous fat.

  2. Cognitive Research

    Brain Structure & Function

    Regional brain volume and cognitive measures are a further area of research interest for this compound, studied via IGF-1 signalling.

  3. Endocrinology

    GH/IGF-1 Axis

    Research model for studying GHRH receptor pharmacology, GH secretagogue effects, and downstream IGF-1 modulation in the context of GH axis research models.

  4. Cardiometabolic

    Lipid & Cardiovascular Markers

    Studies report triglyceride, non-HDL cholesterol and carotid intima-media thickness measures in the published clinical literature, which is why the GH axis is studied against cardiovascular risk markers.

Specification

Chemical NameTrans-3-hexenoic acid-GRF(1-44)-amide
SequenceModified GHRH(1-44) analog (44 amino acids)
Molecular Weight5135.8 Da
Molecular FormulaC₂₂₁H₃₆₆N₇₂O₆₇S
FormLyophilized powder
Purity≥99% (HPLC verified)
TestingThird-party HPLC, Mass Spec, Endotoxin
Storage-20°C for long-term stability
SolubilityWater-soluble
COAIncluded with every order

How it's tested

Every lot of Tesamorelin released to the catalog carries a third-party certificate of analysis. 6 documented lots are on file for this compound, with reported HPLC purity from 99.25% to 99.93% (mean 99.62%), issued by Accurate Test Labs and Freedom Diagnostics. 6 of 6 certificates record identity as confirmed.

Documented lots
6
Reported purity
99.25% to 99.93%
Mean purity
99.62%
Issuing labs
Accurate Test Labs, Freedom Diagnostics

All certificates in the COA library →

Frequently asked questions

What is tesamorelin and how is it different from growth hormone?

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH), specifically a modified version of GHRH(1-44) with a trans-3-hexenoic acid group added to extend stability. Unlike exogenous growth hormone, tesamorelin acts on the pituitary to release endogenous GH, preserving the pulsatile release pattern and the feedback regulation that exogenous GH bypasses.

Is tesamorelin FDA approved?

An approved pharmaceutical formulation of tesamorelin exists for one narrow clinical indication. The research-grade tesamorelin sold on eonpeptides.com is not that product: it is for in vitro research purposes only and is not the approved pharmaceutical product.

How is tesamorelin characterised in visceral adipose research?

Tesamorelin is studied for GH-mediated activation of hormone-sensitive lipase in visceral adipose depots specifically, rather than subcutaneous fat. That depot selectivity is the property of research interest.

What is the cognitive research interest in tesamorelin?

Emerging research is exploring tesamorelin's potential effects on brain structure and cognitive function via elevated IGF-1 signaling. Brain volume and verbal memory measures in cognitive models are an active area of investigation for this compound.

What is tesamorelin's regulatory status?

Tesamorelin is not approved for human use and this material is supplied exclusively for in vitro laboratory research. Handling precautions are the same as for any research peptide; no human safety profile is offered for the material sold here.

How should research-grade tesamorelin be stored?

Lyophilized tesamorelin should be stored at -20°C and protected from moisture and light. The trans-3-hexenoic acid modification raises resistance to dipeptidyl peptidase IV (DPP-IV) cleavage compared to native GHRH, but the material should still be handled carefully to preserve biological activity.

For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.